Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Clinical Drug Development & Investigations

Symposium 13: Clinical Pharmacology Challenges in Obesity & Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Mechanisms & Therapeutics

2 - Pathophysiologic Changes, Staging, Diagnosis & Trial Endpoints for NAFLD/NASH

Tuesday, September 12, 2023

1:30 PM - 3:00 PM PT

Faculty(s)

Manal Abdelmalek, MD, MPH

Professor of Medicine, Director, Hepatobiliary Disease Interest Group, Div. of Gastroenterology & Hepatology
Mayo Clinic

"> Slides

Disclosure(s):

Manal Abdelmalek, MD, MPH: 89 Bio: Consultant/Advisory Board (); Celgene/ Bristol-Myers Squibb: Consultant/Advisory Board (); Clinical Care Options: Consultant/Advisory Board (); Fishawack, Inc: Consultant/Advisory Board (); Hanmi: Consultant/Advisory Board (); Intercept: Consultant/Advisory Board (); Inventiva: Consultant/Advisory Board (); Madrigal: Consultant/Advisory Board (); Medscape: Consultant/Advisory Board (); Merck: Consultant/Advisory Board (); NGM Bio: Consultant/Advisory Board (); Novo Nordisk: Consultant/Advisory Board (); SonicIncytes: Consultant/Advisory Board (); Terra Firma, Inc.: Consultant/Advisory Board (); Theratechnologies: Consultant/Advisory Board ()